[{"NetIncomeLoss_1_Q1_USD":-136141000.0,"RestrictedCashCurrent_0_Q1_USD":10687000.0,"InventoryFinishedGoods_0_Q1_USD":5679000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":56000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-182424000.0,"AssetsCurrent_0_Q1_USD":1070936000.0,"OtherNoncashIncomeExpense_1_Q1_USD":-325000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":405230000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":53258000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":8118221.0,"AvailableForSaleSecurities_0_Q1_USD":1016228000.0,"CommonStockSharesIssued_0_Q1_shares":67439477.0,"Assets_0_Q1_USD":1597763000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":-633000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":38511000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":10656000.0,"CommonStockSharesAuthorized_0_Q1_shares":250000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":99395000.0,"AccruedLiabilitiesCurrent_0_Q1_USD":82699000.0,"OperatingIncomeLoss_1_Q1_USD":-106569000.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q1_USD":144000.0,"EquitySecuritiesFvNiGainLoss_1_Q1_USD":-20619000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-795000.0,"AccountsReceivableNetCurrent_0_Q1_USD":25032000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":379000.0,"CommonStockValue_0_Q1_USD":67000.0,"AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_0_Q1_USD":81624000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":3367000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":156000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":12649000.0,"IncreaseDecreaseInInventories_1_Q1_USD":-474000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-136774000.0,"OtherAssetsNoncurrent_0_Q1_USD":8929000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":383794000.0,"Liabilities_0_Q1_USD":543181000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1_Q1_USD":12761000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-348000.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q1_USD":1016316000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":67102342.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":581614000.0,"InventoryNet_0_Q1_USD":12462000.0,"InvestmentIncomeInterest_1_Q1_USD":639000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-159346000.0,"ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1_Q1_USD":14980000.0,"InventoryWorkInProcess_0_Q1_USD":6783000.0,"LiabilitiesCurrent_0_Q1_USD":127044000.0,"AccountsPayableCurrent_0_Q1_USD":15744000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":68034000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_1_Q1_USD":-771000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":25393000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q1_USD":131031000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q1_USD":-285000.0,"AdditionalPaidInCapital_0_Q1_USD":2810176000.0,"AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0_Q1_USD":-88000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q1_USD":396402000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q1_USD":33306000.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_1_Q1_USD":0.0,"ProceedsFromPaymentsForOtherFinancingActivities_1_Q1_USD":-112000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":87570000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":24220000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-135762000.0,"Goodwill_0_Q1_USD":44406000.0,"InvestmentsFairValueDisclosure_0_Q1_USD":1150365000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":68000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":25089000.0,"PreferredStockValue_0_Q1_USD":null,"LiabilitiesAndStockholdersEquity_0_Q1_USD":1597763000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":33850000.0,"PreferredStockSharesAuthorized_0_Q1_shares":25000000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":24298000.0,"OperatingExpenses_1_Q1_USD":205964000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1_Q1_USD":224240000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-2.03,"StockholdersEquity_0_Q1_USD":1054582000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":16414000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-940000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1755717000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":-329892000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":1993000.0,"CommonStockSharesOutstanding_0_Q1_shares":67439477.0,"RestrictedCashNoncurrent_0_Q1_USD":1921000.0,"ProfitLoss_1_Q1_USD":-136141000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":147518000.0,"Ticker":"RARE","CIK":"1515673","name":"ULTRAGENYX PHARMACEUTICAL INC.","OfficialName":"Ultragenyx Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"5418950849.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210505"}]